Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $30.56

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been given an average recommendation of “Moderate Buy” by the fourteen brokerages that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $30.56.

A number of analysts have recently issued reports on KROS shares. Truist Financial reduced their target price on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, April 9th. Scotiabank lowered their target price on Keros Therapeutics from $41.00 to $26.00 and set a “sector outperform” rating on the stock in a research note on Monday, May 12th. HC Wainwright dropped their target price on Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Wells Fargo & Company decreased their price target on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. Finally, Bank of America lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $32.00 to $18.00 in a research note on Tuesday, June 10th.

Keros Therapeutics Price Performance

Keros Therapeutics stock opened at $13.56 on Wednesday. Keros Therapeutics has a 12-month low of $9.12 and a 12-month high of $72.37. The stock has a market capitalization of $550.74 million, a PE ratio of -2.60 and a beta of 1.31. The firm has a 50 day simple moving average of $13.81 and a 200-day simple moving average of $16.23.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $3.63. The business had revenue of $211.25 million for the quarter, compared to the consensus estimate of $84.62 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same period in the previous year, the firm earned ($1.21) EPS. On average, analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the acquisition, the insider now owns 4,392,737 shares in the company, valued at $44,498,425.81. This trade represents a 27.01% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 20.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Keros Therapeutics

A number of institutional investors have recently modified their holdings of the company. Rhumbline Advisers raised its holdings in Keros Therapeutics by 9.3% in the 1st quarter. Rhumbline Advisers now owns 44,669 shares of the company’s stock worth $455,000 after acquiring an additional 3,802 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of Keros Therapeutics in the first quarter valued at about $1,502,000. Goldman Sachs Group Inc. increased its stake in shares of Keros Therapeutics by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after purchasing an additional 205,022 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Keros Therapeutics by 15.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock worth $227,000 after purchasing an additional 2,982 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in Keros Therapeutics during the 1st quarter valued at approximately $226,000. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.